South Africa suspends AstraZeneca’s vaccine after a research discovered it was not protected against new variants and triggered international alarms – Endpoints Information

Three years after the renaming of Novacap, Seqens, a French pharmaceutical manufacturer and ingredient supplier, is set to be prepared for sale.

The sale comes as the private equity owners of Seqens – the majority shareholder is Eurazeo – hope to capitalize on the current high valuations in the healthcare market, Reuters reported Monday, citing two unnamed sources close to the matter.

Eurazeo, a French investment firm, has hired JP Morgan to find a buyer for the company who could be valued at over $ 2.4 billion. Seqens produces and sells aspirin and paracetamol, among others. In the last fiscal year, the company achieved a profit of around 180.9 million US dollars (150 million euros). That said, its sales value could be 15 times its core profit.

Continue reading

Comments are closed.